Shree Ganesh Biotech India Stock Hits All-Time Low Amid Prolonged Downtrend

On 19 Nov 2025, Shree Ganesh Biotech India’s share price touched Rs.0.67, setting a fresh 52-week and all-time low. This price movement comes amid a day change of -1.45%, underperforming the Sensex which recorded a marginal gain of 0.04% on the same day. The stock also underperformed its sector by 0.75% today, indicating relative weakness compared to its peers.

Examining the moving averages, the stock is trading below all key benchmarks including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests sustained downward momentum over multiple time frames.

Performance metrics over various periods highlight the extent of the decline. Over one day, the stock fell by 1.45%, while the Sensex remained nearly flat. Over one week, Shree Ganesh Biotech India’s stock price declined by 6.85%, contrasting with a 0.28% gain in the Sensex. The one-month performance shows a drop of 8.11% against the Sensex’s 0.90% rise. Over three months, the stock’s loss widened to 12.82%, while the Sensex gained 3.75%.

Longer-term data reveals a more pronounced decline. Over one year, the stock has fallen by 36.45%, while the Sensex recorded a gain of 9.19%. Year-to-date figures show a similar trend with a 34.62% decrease for Shree Ganesh Biotech India compared to an 8.40% increase in the Sensex. The three-year performance is particularly stark, with the stock down 63.24% against a 37.37% rise in the Sensex. Over five years, the stock has declined by 87.80%, whereas the Sensex has risen by 94.28%. The ten-year performance shows no change for the stock, while the Sensex has appreciated by 227.78%.

Financial metrics provide further insight into the company’s current standing. The company’s market capitalisation grade is 4, indicating a relatively modest market cap within its sector. The Mojo Score stands at 3.0, with a Mojo Grade classified as Strong Sell as of 8 Aug 2024, reflecting an adjustment in evaluation based on recent performance and fundamentals.

Shree Ganesh Biotech India’s financial results for the nine months ending September 2025 show net sales at Rs.5.16 crore, representing a contraction of 44.64% compared to the previous period. The profit after tax (PAT) for the same period is reported at a loss of Rs.0.61 crore, also reflecting a decline of 44.64%. The company’s debtors turnover ratio for the half year is recorded at 0.00 times, indicating challenges in receivables management.

The company’s ability to service its debt is constrained, with an average EBIT to interest ratio of 0.91. This figure suggests limited coverage of interest expenses by earnings before interest and tax. Return on equity (ROE) averaged at 2.62%, signalling low profitability relative to shareholders’ funds.

Profitability trends further underscore the situation. Over the past year, while the stock has generated a return of -36.45%, profits have declined by 86.6%. The company’s earnings before interest, tax, depreciation and amortisation (EBITDA) are negative, contributing to the perception of elevated risk in the stock’s valuation compared to its historical averages.

Ownership structure indicates that the majority shareholders are non-institutional, which may influence liquidity and trading dynamics.

In summary, Shree Ganesh Biotech India’s stock has experienced a sustained decline culminating in a new all-time low price of Rs.0.67. The stock’s underperformance relative to the Sensex and its sector, combined with subdued financial results and key ratios, reflects a challenging environment for the company within the Pharmaceuticals & Biotechnology sector. The trading below all major moving averages and the negative EBITDA further illustrate the current market sentiment and valuation concerns.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →